Rubicon Research Limited Holds 27th AGM on August 26, 2026
Rubicon Research Limited held its 27th AGM on August 26, 2026. Key agenda items included approving FY26 financial statements, a final dividend, and a merger scheme. The company also discussed its IPO milestone in FY25-26 and its evolution into a specialty products company, showcasing strong financial growth and expanded capabilities.
The AGM discussed several significant corporate actions including a merger, dividend declaration, and stock option plans, which are material to the company's operations and shareholder value.
The announcement is a routine disclosure of the proceedings of an Annual General Meeting. While it covers important corporate actions like a merger and dividend, it does not contain new financial results or strategic shifts that would significantly alter the company's outlook.
Rubicon Research Limited (formerly Rubicon Research Private Limited) held its 27th Annual General Meeting (AGM) on Wednesday, August 26, 2026, commencing at 1:00 PM IST and concluding at 2:40 PM IST via Video Conferencing (VC)/Other Audio-Visual Means (OAVM) Facility. The meeting was conducted in compliance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A total of 71 members attended the AGM. The agenda included the consideration and adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, declaration of a final dividend, re-appointment of a director, approval of remuneration for Non-executive Independent Directors, the Rubicon Research Limited Stock Options Plan 2026 and its extension to subsidiaries, appointment of secretarial auditors, and approval of the Scheme of Merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, with Rubicon Research Limited. The Executive Director & CEO, Mr. Parag Sanchetti, addressed the members, highlighting the company's journey and the milestone IPO in FY 2025-26. The company will separately disclose the results of the remote e-voting and e-voting at the AGM to the stock exchanges in due course.
The AGM covered ordinary business including the adoption of financial statements for FY 2025-26, declaration of a final dividend, and the re-appointment of Mrs. Pratibha Pilgaonkar as a Director. Special business included the approval of remuneration for Non-executive Independent Directors, the Rubicon Research Limited Stock Options Plan 2026 and its extension to subsidiaries, the appointment of M/s. BNP & Associates as Secretarial Auditors, and the crucial approval of the Scheme of Merger of KIA Health Tech Private Limited with Rubicon Research Limited under Section 233 of the Companies Act, 2013.
The meeting also provided an overview of the company's performance, its evolution into a specialty products company, consolidated financial performance showing significant growth in revenue and net profit for FY26, and its robust manufacturing and R&D capabilities. The company highlighted its strong regulatory track record and strategic M&A initiatives aimed at expanding its capabilities in manufacturing and distribution.
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.